To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) - Trial NCT06341660
Access comprehensive clinical trial information for NCT06341660 through Pure Global AI's free database. This Phase 2 trial is sponsored by Guangzhou Institute of Respiratory Disease and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Guangzhou Institute of Respiratory Disease
Timeline & Enrollment
Phase 2
May 25, 2023
Jul 01, 2025
Primary Outcome
Safety assessments and ORR
Summary
To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as
 first-line treatment in patients with KeAP1-mutated advanced or postoperative recurrent
 non-small cell lung cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06341660
Non-Device Trial